"The voice for cancer physicians and their patients in Massachusetts."

  • Home
  • For Professionals
  • FDA Approvals
  • FDA approves olaparib (Lynparza) plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers

FDA approves olaparib (Lynparza) plus bevacizumab as maintenance treatment for ovarian, fallopian tube, or primary peritoneal cancers

11 May 2020 2:37 PM | Anonymous

The U.S. Food and Drug Administration expanded the indication of olaparib (LYNPARZA, AstraZeneca Pharmaceuticals, LP) to include its combination with bevacizumab for first-line maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency positive status defined by either a deleterious or suspected deleterious BRCA mutation, and/or genomic instability. Read full press release.

© Copyright.  All rights reserved. 

Massachusetts Society of Clinical Oncologists

P.O. Box 549154, Waltham, MA, 02454
Tel: 781.434.7329 | Fax: 781.464.4896 | email: msco@mms.org

Powered by Wild Apricot Membership Software